PRTA - Prothena Corporation plc
About Prothena Corporation plc (https://www.prothena.com)
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, which is in Phase IIb clinical trial for the treatment of Parkinson's disease; PRX004 that completed Phase I clinical trial for the treatment of Transthyretin amyloidosis; and PRX005, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX012 for the treatment of Alzheimer's disease; and dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target alpha-synuclein; and a collaboration agreement with Bristol-Myers Squibb to develop antibodies. The company was founded in 2012 and is based in Dublin, Ireland.
Key Executives
| NAME | TITLE | DOB | SALARY |
|---|---|---|---|
| Gene G. Kinney | President, Chief Executive Officer & Director | 1969 | $1,124,507 USD |
| Tran Nguyen | Chief Financial Officer | 1974 | $916,334 USD |
| Brandon S. Smith | Chief Operating Officer | 1975 | $826,819 USD |
| Chad Swanson | Chief Development Officer | – | $739,084 USD |
| Wagner Zago | Chief Scientific Officer | 1973 | $735,660 USD |
| Michael J. Malecek | Chief Legal Officer & Company Secretary | 1966 | $588,250 USD |
| Annie Evans Kingston | Chief Strategy Officer | – | – |
| Karin L. Walker | Chief Accounting Officer & Controller | 1963 | – |
| Mark C. Johnson | Vice President of Investor Relations | – | – |
| Phillip Dolan | Sr. Director & Head of Exploratory Research | – | – |